Processa Pharmaceuticals, Inc.
PCSA
$0.25
-$0.01-3.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.53% | 19.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.69% | 38.77% | |||
| Operating Income | 11.69% | -38.77% | |||
| Income Before Tax | 12.64% | -38.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.64% | -38.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.64% | -38.79% | |||
| EBIT | 11.69% | -38.77% | |||
| EBITDA | 11.69% | -38.77% | |||
| EPS Basic | 71.39% | 15.06% | |||
| Normalized Basic EPS | 71.37% | 15.06% | |||
| EPS Diluted | 71.39% | 15.06% | |||
| Normalized Diluted EPS | 71.37% | 15.06% | |||
| Average Basic Shares Outstanding | 205.25% | 63.43% | |||
| Average Diluted Shares Outstanding | 205.25% | 63.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||